Literature DB >> 26163359

Potential Molecular Mechanism of Retrograde Aortic Arch Stenosis in the Hybrid Approach to Hypoplastic Left Heart Syndrome.

Narutoshi Hibino1, Mary J Cismowski2, Brenda Lilly2, Patrick I McConnell3, Toshiharu Shinoka3, John P Cheatham4, Pamela A Lucchesi2, Mark E Galantowicz3, Aaron J Trask5.   

Abstract

BACKGROUND: The hybrid palliation for hypoplastic left heart syndrome has emerged as an alternative approach to the Norwood procedure. The development of patent ductus arteriosus (PDA) in-stent stenosis can cause retrograde aortic arch stenosis (RAAS), leading to significant morbidity. This study aimed to identify potential mechanisms of PDA in-stent stenosis contributing to RAAS.
METHODS: Tissues from stented PDAs were collected from 17 patients undergoing comprehensive stage II repair between 2009 and 2014. Patients requiring RAAS intervention based on cardiology-surgery consensus were defined as RAAS(+) (n = 10), whereas patients without any RAAS intervention were defined as RAAS(-) (n = 7). Tissues were examined by quantitative polymerase chain reaction analysis for vascular smooth muscle cell (VSMC) differentiation and proliferation markers.
RESULTS: Patient characteristics were hypoplastic left heart syndrome with aortic atresia in 6 and with aortic stenosis in 3; unbalanced atrioventricular canal in 3; double-inlet left ventricle/transposition of the great arteries in 3; and double-outlet right ventricle in 2. VSMC differentiation markers (β-actin, SM22, and calponin) and signaling pathways for VSMC modulation (transforming growth factor-β1, Notch, and platelet derived growth factor-BB) were significantly higher in the RAAS(+) than in RAAS(-) patients. The proliferation marker Ki67 was increased in RAAS(+) patients. Cell cycle markers were comparable in both groups.
CONCLUSIONS: Increased VSMC differentiation and proliferation markers suggest a mechanism for inward neointima formation of the PDA in RAAS. The apparent lack of change in cell cycle markers is contrary to coronary artery in-stent stenosis, suggesting further targets should be examined. Combined primary in vitro PDA cell culture and proteomics can be strong tools to elucidate targets to reduce PDA in-stent stenosis for RAAS in the future.
Copyright © 2015 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26163359      PMCID: PMC4567479          DOI: 10.1016/j.athoracsur.2015.04.125

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  31 in total

Review 1.  The porcine coronary model of in-stent restenosis: current status in the era of drug-eluting stents.

Authors:  Harry C Lowe; Robert S Schwartz; Briain D Mac Neill; Ik-Kyung Jang; Motoya Hayase; Campbell Rogers; Stephen N Oesterle
Journal:  Catheter Cardiovasc Interv       Date:  2003-12       Impact factor: 2.692

Review 2.  Molecular basis of restenosis and drug-eluting stents.

Authors:  Marco A Costa; Daniel I Simon
Journal:  Circulation       Date:  2005-05-03       Impact factor: 29.690

Review 3.  In stent restenosis: bane of the stent era.

Authors:  A K Mitra; D K Agrawal
Journal:  J Clin Pathol       Date:  2006-03       Impact factor: 3.411

4.  Current assessment of mortality rates in congenital cardiac surgery.

Authors:  Karl F Welke; Irving Shen; Ross M Ungerleider
Journal:  Ann Thorac Surg       Date:  2006-07       Impact factor: 4.330

5.  T-type Ca2+ channels promote oxygenation-induced closure of the rat ductus arteriosus not only by vasoconstriction but also by neointima formation.

Authors:  Toru Akaike; Mei-Hua Jin; Utako Yokoyama; Hiroko Izumi-Nakaseko; Qibin Jiao; Shiho Iwasaki; Mari Iwamoto; Shigeru Nishimaki; Motohiko Sato; Shumpei Yokota; Yoshinori Kamiya; Satomi Adachi-Akahane; Yoshihiro Ishikawa; Susumu Minamisawa
Journal:  J Biol Chem       Date:  2009-06-30       Impact factor: 5.157

Review 6.  Cell cycle checkpoints: preventing an identity crisis.

Authors:  S J Elledge
Journal:  Science       Date:  1996-12-06       Impact factor: 47.728

7.  p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest.

Authors:  K Polyak; J Y Kato; M J Solomon; C J Sherr; J Massague; J M Roberts; A Koff
Journal:  Genes Dev       Date:  1994-01       Impact factor: 11.361

8.  Transforming growth factor-β and smooth muscle differentiation.

Authors:  Xia Guo; Shi-You Chen
Journal:  World J Biol Chem       Date:  2012-03-26

9.  Stenting of the arterial duct combined with banding of the pulmonary arteries and atrial septectomy or septostomy: a new approach to palliation for the hypoplastic left heart syndrome.

Authors:  J L Gibbs; C Wren; K G Watterson; S Hunter; J R Hamilton
Journal:  Br Heart J       Date:  1993-06

10.  Hybrid approach for hypoplastic left heart syndrome: intermediate results after the learning curve.

Authors:  Mark Galantowicz; John P Cheatham; Alistair Phillips; Clifford L Cua; Timothy M Hoffman; Sharon L Hill; Roberta Rodeman
Journal:  Ann Thorac Surg       Date:  2008-06       Impact factor: 4.330

View more
  1 in total

1.  Inhibition of the methyltranferase EZH2 improves aortic performance in experimental thoracic aortic aneurysm.

Authors:  Christian L Lino Cardenas; Chase W Kessinger; Carolyn MacDonald; Arminder S Jassar; Eric M Isselbacher; Farouc A Jaffer; Mark E Lindsay
Journal:  JCI Insight       Date:  2018-03-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.